Attention-deficit/hyperactivity disorder: An update on medication adherence and persistence in children, adolescents and adults

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 13, Issue 6, 2013, Pages 791-815

  Ahmed, Rana ^a   Aslani, Parisa ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Attention deficit hyperactivity disorder; medication adherence; medication compliance; medication persistence; psychostimulant; review

Indexed keywords

AMPHETAMINE DERIVATIVE; ATOMOXETINE; DEXAMPHETAMINE; LONG ACTING DRUG; METHYLPHENIDATE; SHORT ACTING DRUG;

ADOLESCENT; ADULT; AGE; ATTENTION DEFICIT DISORDER; CAUCASIAN; CHILD; COMORBIDITY; DRUG EFFICACY; DRUG FORMULATION; DRUG MEGADOSE; FAMILY; FAMILY HISTORY; HUMAN; MORNING DOSAGE; PATIENT CARE; PATIENT COMPLIANCE; PREDICTION; REVIEW; STANDARDIZATION; STIGMA; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; AGE FACTORS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; FAMILY HEALTH; HUMANS; MEDICATION ADHERENCE; TREATMENT OUTCOME;

EID: 84887955192     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/14737167.2013.841544     Document Type: Review

References (88)

1. Chacko A, Newcorn JH, Feirsen N, Uderman JZ. Improving medication adherence in chronic pediatric health conditions: A focus on ADHD in youth. Curr. Pharm. Des. 16(22), 2416-2423 (2010).
2. World Health Organization. Adherence to Long Term Therapies: A Call to Action. World Health Organization, Geneva, Switzerland (2003).
3. Clay D, Farris K, Mccarthy AM, Kelly MW, Howarth R. Family perceptions of medication administration at school: errors, risk factors, and consequences. J. Sch. Nurs. 24(2), 95-102 (2008).
4. Krueger KP, Berger BA, Felkey B. Medication adherence and persistence: A comprehensive review. Adv. Ther. 22(4), 313-356 (2005).
5. Farris KB, McCarthy AM, Kelly MW, Clay DL, Gross JL. Issues of medication administration and control in Iowa schools. J. Sch. Health 73(9), 331-37 (2003).
6. Rapoff MA. Adherence to Pediatric Medical Regimens. Plenum Publishers, New York, USA (1999).
7. Buckley P. Adherence to Mental Health Treatment. Oxford University Press, New York, USA (2009).
8. Osterberg L, Blaschke T. Adherence to medication. N. Engl. J. Med. 353(5), 487-497 (2005).
9. Fredericks EM, Magee JC, Opipari-Arrigan L, Shieck V, Well A, Lopez MJ. Adherence and health-related quality of life in adolescent liver transplant recipients. Pediatr. Transplant. 12(3), 289-299 (2008).
10. Drotar D, Greenley RN, Demeter CA et al. Adherence to pharmacological treatment for juvenile bipolar disorder. J. Am. Acad. Child Adol. Psychiatry 46(7), 831-839 (2007).
11. Hommel KA, Davis CM, Baldassano RN. Medication adherence and quality of life in pediatric inflammatory bowel disease. J. Pediatr. Psychol. 33(8), 867-874 (2008).
12. Ekberg H, Kyllonen L, Madsen S, Grave G, Solbu D, Holdaas H. Clinicians underestimate gastrointestinal symptoms and overestimate quality of life in renal transplant recipients: A multinational survey of nephrologists. Transplantation 84(8), 1052-1054 (2007).
13. Lehane E, Mccarthy G. Medication non-adherence-exploring the conceptual mire. Int. J. Nurs. Practice 15(1), 25-31 (2009).
14. Horwitz RI, Horwitz SM. Adherence to treatment and health outcomes. Arch. Intern. Med. 153(16), 1863-1868 (1993).
15. The Coronary Drug Project Research Group. Influence of adherence to treatment and response of cholesterol on mortality in the Coronary Drug Project. N. Engl. J. Med. 303(18), 1038-1041 (1980).
16. National Council on Patient Information and Education. Enhancing Prescription Medicine Adherence. A National Action Plan. National Council on Patient Information and Education, Rockville, MD, USA (2007).
17. World Health Organization. Global Status Report on Non-Communicable Diseases 2010. World Health Organization, Geneva, Switzerland (2010).
18. Matsui D. Current issues in pediatric medication adherence. Pediatr. Drugs 9(5), 283-288 (2007).
19. La Greca AM. Issues in adherence with pediatric regimens. J. Pediatr. Psychol. 15(4), 423-436 (1990).
20. Winnick S, Lucas DO, Hartman AL, Toll D. How do you improve compliance Pediatrics 115(6), e718-e724 (2005).
21. Hummelinck A, Pollock K. Parents' information needs about the treatment of their chronically ill child: A qualitative study. Patient Educ. Couns. 62, 228-234 (2005).
22. Charach A. ADHD treatment: Strategies for optimizing adherence. Consultant 51(11), 824-833 (2011).
23. Bokhari FAS, Heiland F, Levine P, Ray GT. Risk factors for discontinuing drug therapy among children with ADHD. Health Serv. Outcomes Res. Methodol. 8(3), 134-158 (2008).
24. Khoza S, Oladapo AO, Barner JC. Adherence to medication for attention deficit/hyperactivity disorder: Does time frame matter J. Pharm. Health Serv. Res. 2(3), 157-163 (2011).
25. Wilens TE, Dodson W. A clinical perspective of attention-deficit/ hyperactivity disorder into adulthood. J. Clin. Psychiatry 65, 1301-1313 (2004).
26. Wolraich ML, Wibbelsman CJ, Brown TE et al. Attention deficit/hyperactivity disorder among adolescents: A review of diagnosis, treatment, and clinical implications. Pediatrics 115, 1734-1746 (2005).
27. Summers JA, Caplan PJ. Laypeople's attitudes toward drug treatment for behavioural control depend on which disorder and which drug. Clin. Pediatr. 26, 258-263 (1987).
28. Wilcutt EG. The prevalence of DSM-IV attention-deficit/hyperactivity disorder: A meta-analytic review. Neurother. 9, 490-499 (2012).
29. Simon V, Czobor P, Balint S, Meszaros A, Bitter I. Prevalence and correlates of adult attention-deficit hyperactivity disorder: meta-analysis. Brit. J. Psychiat. 194, 204-211 (2009).
30. Lien MT, Carlson JS, Hunter-Oehmke S, Knapp KA. A pilot investigation of teachers' perceptions of psychotropic drug use in schools. J. Atten. Disord. 11, 172-178 (2007).
31. Culpepper L. Primary care treatment of attention-deficit/hyperactivity disorder. J. Clin. Psychiat. 67(Suppl. 8), 51-58 (2006).
32. National Health and Medical Research Council. Clinical Practice Points on the diagnosis, assessment and management of attention deficit hyperactivity disorder in children and adolescents. NHMRC Publications, Canberra, Commonwealth of Australia (2012).
33. Wolraich M, Brown L, Brown RT et al. ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics 128(5), 1007-1022 (2011).
34. Knutson KC, O'Malley M. Adult attentiondeficit/hyperactivity disorder: A survey of diagnosis and treatment practices. J. Am. Acad. Nurse Pract. 22, 593-601 (2009).
35. Murray DW. Treatment of preschoolers with attention-deficit/hyperactivity disorder. Curr. Psychiatry Rep. 12, 374-381 (2010).
36. Jadad AR, Booker L, Gauld M et al. The treatment of attention-deficit hyperactivity disorder: An annotated bibliography and critical appraisal of published systematic reviews and meta-analyses. Can. J. Psychiat. 44(10), 1025-1035 (1999).
37. Kaplan G, Newcorn JH. Pharmacotherapy for child and adolescent attention-deficit hyperactivity disorder. Pediatr. Clin. North Am. 58, 99-120 (2011).
38. Faraone SV, Biederman J, Spencer TJ, Aleardi M. Comparing the efficacy of medications for ADHD using meta-analysis. Med. Gen. Med. 8(4), 4 (2006).
39. Pliszka SR, Crimson ML, Hughes CW et al. Texas Consensus Conference Panel on pharmacotherapy of childhood attention deficit hyperactivity disorder. Revision of the algorithm for pharmacotherapy of attention deficit/hyperactivity disorder. J. Am. Acad. Child Adolesc. Psychiatry 45, 642-657 (2006).
40. Elia J, Ambrosini PJ, Rapoport JL. Treatment of attention-deficit hyperactivity disorder. N. Engl. J. Med. 340, 780-788 (1999).
41. Pliszka S. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J. Am. Acad. Child Adolesc. Psychiatry 7, 849-921 (2007).
42. Dopheide JA. The role of pharmacotherapy and managed care pharmacy interventions in the treatment of ADHD. Am. J. Manag. Care 15(5 Suppl.), S141-S150 (2009).
43. Dopheide JA, Pliszka SR. Attention-deficit-hyperactivity disorder: An update. Pharmacotherapy 29(6), 656-679 (2009).
44. Merkel RL, Kuchibhalta A. Safety of stimulant treatment in attention deficit hyperactivity disorder: part I. Expert Opin. Drug Saf. 8, 655-668, (2009).
45. Merkel RL. Safety of stimulant treatment in attention deficit hyperactivity disorder: part II. Expert Opin. Drug Saf. 9, 917-935, (2010).
46. Ferrin M, Ruiz-Veguilla M, Blanc-Betes M et al. Evaluation of attitudes towards treatment in adolescents with attention deficit hyperactivity disorder (ADHD). Eur. Child Adolesc. Psychiatry 21(7), 387-401 (2012).
47. Marcus SC, Wan GJ, Kemner JE, Olfson M. Continuity of methylphenidate treatment for attention-deficit/hyperactivity disorder. Arch. Pediatr. Adolesc. Med. 159(6), 572-578 (2005).
48. Charach A, Volpe T, Boydell KM, Gearing RE. A theoretical approach to medication adherence for children and youth with psychiatric disorders. Harv. Rev. Psychiatry 16(2), 126-135 (2008).
49. Safren SA, Duran P, Yovel I, Perlman CA, Sprich S. Medication adherence in psychopharmacologically treated adults with ADHD. J. Atten. Disord. 10(3), 257-260 (2007).
50. Adler LD, Nierenberg AA. Review of medication adherence in children and adults with ADHD. Postgrad. Med. 122(1), 184-191 (2010).
51. Woodruff TJ, Axelrad DA, Kyle AD, Nweke O, Miller GG, Hurley BJ. Trends in environmentally related childhood illnesses. Pediatrics, 113(4 Suppl.), 1133-1140 (2004).
52. Chan E, Zhan C, Homer CJ. Health care use and costs for children with attentiondeficit/hyperactivity disorder: National estimates from the Medical Expenditure Panel Survey. Arch. Pediatr. Adolesc. Med. 156, 504-511 (2002).
53. Cramer JA, Roy A, Burrell A et al. Medication compliance and persistence: Terminology and definitions. Value Health 11(1), 44-47 (2008).
54. Vlasnik JJ, Aliotta SL, Delor B. Medication adherence: factors influencing compliance with prescribed medication plans. Case. Manager 16(2), 47-51 (2005).
55. Caisley H, Muller U. Adherence to medication in adults with attention deficit hyperactivity disorder and pro re nata dosing of psychostimulants: A systematic review. Eur. Psychiatry 27(5), 343-349 (2012).
56. Horne R, Weinman J, Barber N et al. Concordance, Adherence and Compliance in Medicine Taking. National Coordinating Centre for NHS Service Delivery and Organisation, London, UK (2006).
57. Rudd P, Byyny RL, Zachary V et al. Pill count measures of compliance in a drug trial: variability and suitability. Am. J. Hypertens. 1, 309-312 (1988).
58. Pullar T, Kumar S, Tindall H, Feely M. Time to stop counting the tablets Clin. Pharmacol. Ther. 46, 163-168 (1989).
59. Cramer JA, Mattson RH, Prevey ML, Scheyer RD, Ouellette VL. How often is medication taken as prescribed A novel assessment technique. JAMA 261, 3273-3277 (1989).
60. Knafl GJ, Schoenthaler A, Ogedegbe G. Secondary analysis of electronically monitored medication adherence data for a cohort of hypertensive African-Americans. Patient Prefer. Adherence 6, 207-219 (2012).
61. Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records. Methods, validity, and applications. J. Clin. Epidemiol. 50, 105-116 (1997).
62. Ishisaka DY, Jukes T, Romanelli RJ, Wong KS, Schiro TA. Disparities in adherence to and persistence with antihypertensive regimens: An exploratory analysis from a community-based provider network. J. Am. Soc. Hypertens. 6(3), 201-209 (2012).
63. Gau SS-F, Chen S-J, Chou W-J et al. National survey of adherence, efficacy, and side effects of methylphenidate in children with attention-deficit/hyperactivity disorder in Taiwan. J. Clin. Psychiatry 69(1), 131-140 (2008).
64. Chou W-J, Chou M-C, Tzang R-F et al. Better efficacy for the osmotic release oral system methylphenidate among poor adherents to immediate-release methylphenidate in the three ADHD subtypes. Psychiatry Clin. Neurosci. 63(2), 167-175 (2009).
65. Tzang RF, Wang YC, Yeh CB et al. Naturalistic exploration of the effect of osmotic release oral system-methylphenidate on remission rate and functional improvement in Taiwanese children with attention-deficit-hyperactivity disorder. Psychiatry Clin. Neurosci. 66(1), 53-63 (2012).
66. Rothenberger A, Becker A, Breuer D, Dopfner M. An observational study of once-daily modified-release methylphenidate in ADHD: quality of life, satisfaction with treatment and adherence. Eur. Child Adolesc. Psychiatry 20(Suppl. 2), S257-S265 (2011).
67. Atzori P, Usala T, Carucci S, Danjou F, Zuddas A. Predictive factors for persistent use and compliance of immediate-release methylphenidate: A 36-month naturalistic study. J. Child Adolesc. Psychopharmacol. 19(6), 673-681 (2009).
68. Yang J, Yoon BM, Lee MS, Joe SH, Jung IK, Kim SH. Adherence with electronic monitoring and symptoms in children with attention deficit hyperactivity disorder. Psychiatry Investig. 9(3), 263-268 (2012).
69. Adler LA, Lynch LR, Shaw DM et al. Medication adherence and symptom reduction in adults treated with mixed amphetamine salts in a randomized crossover study. Postgrad. Med. 123(5), 71-79 (2011).
70. Ramos-Quiroga JA, Bosch R, Castells X et al. Effect of switching drug formulations from immediate-release to extended-release OROS methylphenidate: A chart review of Spanish adults with attention-deficit hyperactivity disorder. CNS Drugs 22(7), 603-611 (2008).
71. Spencer TJ, Mick E, Surman CBH et al. A randomized, single-blind, substitution study of OROS methylphenidate (Concerta) in ADHD adults receiving immediate release methylphenidate. J. Atten. Disord. 15(4), 286-294 (2011).
72. Pappadopulos E, Jensen PS, Chait AR et al. Medication adherence in the MTA: saliva methylphenidate samples versus parent report and mediating effect of concomitant behavioral treatment. J. Am. Acad. Child Adolesc. Psychiatry 48(5), 501-510 (2009).
73. Winterstein AG, Gerhard T, Shuster J et al. Utilization of pharmacologic treatment in youths with attention deficit/hyperactivity disorder in Medicaid database. Ann. Pharmacother. 42(1), 24-31 (2008).
74. Olfson M, Marcus S, Wan G. Stimulant dosing for children with ADHD: A medical claims analysis. J. Am. Acad. Child Adolesc. Psychiatry 48(1), 51-59 (2009).
75. Wong ICK, Asherson P, Bilbow A et al. Cessation of attention deficit hyperactivity disorder drugs in the young (CADDY)-a pharmacoepidemiological and qualitative study. Health Technol. Assess. 13(50), iii-iv, ix-xi, 1-120 (2009).
76. McCarthy S, Wilton L, Murray ML, Hodgkins P, Asherson P, Wong ICK. Persistence of pharmacological treatment into adulthood, in UK primary care, for ADHD patients who started treatment in childhood or adolescence. BMC Psychiatry 12, 219 (2012).
77. Palli SR, Kamble PS, Chen H, Aparasu RR. Persistence of stimulants in children and adolescents with attention-deficit/hyperactivity disorder. J. Child Adolesc. Psychopharmacol. 22(2), 139-148 (2012).
78. Christensen L, Sasane R, Hodgkins P, Harley C, Tetali S. Pharmacological treatment patterns among patients with attention-deficit/hyperactivity disorder: retrospective claims-based analysis of a managed care population. Curr. Med. Res. Opin. 26(4), 977-989 (2010).
79. Lachaine J, Beauchemin C, Sasane R, Hodgkins PS. Treatment patterns, adherence, and persistence in ADHD: A Canadian perspective. Postgrad. Med. 124(3), 139-148 (2012).
80. Hodgkins P, Sasane R, Christensen L, Harley C, Liu F. Treatment outcomes with methylphenidate formulations among patients with ADHD: retrospective claims analysis of a managed care population. Curr. Med. Res. Opin. 27(Suppl. 2), 53-62 (2011).
81. Lawson KA, Johnsrud M, Hodgkins P, Sasane R, Crismon ML. Utilization patterns of stimulants in ADHD in the Medicaid population: A retrospective analysis of data from the Texas Medicaid program. Clin. Ther. 34(4), 944-956 e944 (2012).
82. Charach A, Gajaria A. Improving psychostimulant adherence in children with ADHD. Expert Rev. 8(10), 1563-1571 (2008).
83. Johnston C, Hommersen P, Seipp C. Acceptability of behavioral and pharmacological treatments for attentiondeficit/hyperactivity disorder: relations to child and parent characteristics. Behav. Ther. 39, 22-32, (2008).
84. Peters K, Jackson D. Mothers' experiences of parenting a child with attention deficit hyperactivity disorder. J. Adv. Nurs. 65, 62-71, (2009).
85. Ahmed R, McCaffery KJ, Aslani P. Factors influencing parental decision making about stimulant treatment for attention-deficit/hyperactivity disorder. J. Child Adolesc. Psychopharmacol. 23(3), 163-178 (2013).
86. Frances A. The first draft of DSM-V. BMJ 340, c1168 (2010).
87. Morrow RL, Garland J, Wright JM, Maclure M, Taylor S, Dormuth CR. Influence of relative age on diagnosis and treatment of attention-deficit/ hyperactivity disorder in children. Can. Med. Assoc. J. 184, 755-762 (2012).
88. Moynihan R, Doust J, Henry D. Preventing overdiagnosis: how to stop harming the healthy. BMJ 344, e3502 (2012).